But what if the future of cancer care does not lie in bigger machines, harsher drugs, or more invasive surgeries? What if the next revolution comes from learning how to guide energy through the body with extraordinary precision while simultaneously teaching the immune system to recognize cancer as its enemy?

A growing body of research suggests that this future may already be taking shape. Across several groundbreaking studies, researchers including Prof. Peter Littrup of the University of Rochester have explored how advanced ultrasound imaging, cryoablation, and localized immunotherapy could work together to transform cancer care into something less invasive, more personalized, less costly and with resultant greater availability to far more people around the world.

At first glance, these technologies may seem unrelated, but they’ve been shown to be effective, even though their initial commercial success may simply be delayed. One involves ultrasound imaging, another freezes tumors into blocks of ice and a third involves directly injecting the margins surrounding cancers with immune stimulating drugs. Yet together they point toward a strikingly unified vision of potentially simplifying how cancer medicine could be delivered more effectively and with lower cost. The same systems that detect cancer with extraordinary precision may one day treat it noninvasively while simultaneously turning each patient’s own tumor into a personalized vaccine.

The story begins with ultrasound. Most people are familiar with ultrasound as a tool for viewing pregnancies or examining organs inside the body. Traditional ultrasound works by sending sound waves into tissue and interpreting the echoes that return. It is safe, widely available, and inexpensive compared with magnetic resonance imaging (MRI) or x-ray computed tomography (CT) scanning. Yet conventional hand-held ultrasound has limitations, especially when imaging dense breast tissue where cancers can hide among normal structures. Unlike the 3D CT or MRI datasets, current hand-held ultrasound literally deforms the breast tissues and can make consistent evaluation, or comparisons over time, much more uncertain.

To overcome this challenge, researchers developed an entirely different form of ultrasound known as breast ultrasound tomography (UST). One of the leading systems in this field was SoftVue, a device developed through decades of work involving Prof. Peter Littrup and his colleagues. Instead of relying only on reflected sound waves, the system measures additional physical properties of tissue, including sound speed and attenuation. These 3D measurements are obtained from a circular array that reveals how sound travels through the breast from the chest wall to the nipple. Reconstruction of this complex dataset can then be quantitatively displayed to highlight tissue differences, especially between benign and malignant tumors.

The result is a far richer picture of the breast than standard ultrasound can provide. Women with dense breast tissue face a particularly difficult problem. Dense tissue increases the risk of breast cancer and also makes tumors harder to detect with mammography. SoftVue addressed this challenge by creating detailed three-dimensional maps of breast tissue while improving both sensitivity and specificity. In simple terms, it became better at finding cancers while also reducing false alarms. Equally important, the experience was far more comfortable for patients than mammography, which can cause pain when the breast is compressed between the x-ray plates.

Despite receiving FDA approval as an adjunct to mammography screening, the company behind the technology, Delphinus Medical Technologies, Inc. ultimately closed in 2025 after struggling commercially. Yet the scientific implications of the work did not disappear. In many ways, the initial imaging breakthrough may prove to be only the beginning.

The most intriguing aspect of the research lies in what these ultrasound systems might eventually do beyond diagnosis. The same ring-shaped ultrasound arrays used to create detailed tissue maps can also reverse the process. Instead of simply receiving sound waves, they can focus energy back into tissue with remarkable accuracy. Researchers call this time reversed focused ultrasound. Using the physical information gathered during imaging, the system can compensate for the distortions created by human tissue and precisely direct energy to a target deep inside the body.

This opens the door to therapies that sound almost futuristic. Focused ultrasound can heat tissue, destroy tumors, or temporarily open biological barriers to deliver drugs exactly where they are needed. Combined with microbubble technology, tiny bubbles that can carry medications, or even cells (such as stem cells), through the bloodstream, these systems may one day deliver treatments directly into cancers and along their margins while sparing surrounding healthy tissue.

Prof. Peter Littrup has argued that such systems could become far more affordable and widely available than current MRI-guided focused ultrasound technologies, which remain extremely expensive and limited to major medical centers.

The implications extend well beyond breast cancer. As a Parkinson’s disease patient himself, Prof. Littrup has taken particular interest in the possibility of using low intensity focused ultrasound to deliver therapies into deep brain structures. Researchers are already investigating focused ultrasound for neurological disorders ranging from Parkinson’s disease to Alzheimer’s disease. If less expensive ultrasound tomography systems can perform similar functions, the technology could dramatically expand global access to advanced neurological treatment. UST has also been shown to better penetrate the skull for brain imaging since it already uses sufficiently low frequencies to avoid the image distortions caused by bone, common with current high frequency US.

Yet, imaging and focused ultrasound represent only one part of the emerging vision. Another major component involves cryoablation, a technique that destroys tumors by freezing them. This involves using probes to create expanding ice balls that freeze cancer cells to lethal temperatures.

Unlike surgery, cryoablation often requires only small punctures rather than large incisions. Patients can frequently go home the same day. The freezing process itself even produces a natural numbing effect, making the procedure relatively painless for many patients.

Recently, cryoablation gained acceptance and FDA approval for primarily only small breast tumors. Researchers demonstrated excellent results in carefully selected cancers under 1.5 centimeters in size. But larger tumors posed a challenge because they already carried greater risks of spread to lymph nodes and distant organs.

This is where the work led by Prof. Peter Littrup became especially important. Rather than relying on a single freezing probe, decades of his research explored sophisticated multi probe strategies guided by CT and ultrasound imaging. By carefully placing several cryoprobes throughout larger tumors, physicians could create overlapping ice zones that fully engulfed cancers while extending beyond all apparent tumor margins.

The engineering involved is surprisingly elegant. The body itself acts as a heat source, constantly warming tissue from the inside. To overcome this effect, the placement of cryoprobes must account for subtle differences in heat flow through fat, glandular tissue, and muscle. The studies demonstrated that with proper planning, even relatively large breast tumors could be thoroughly frozen with minimal complications.

But freezing tumors may accomplish something even more important than local destruction. When cancer cells die through cryoablation, they release a flood of tumor antigens and danger signals into the surrounding tissue. In essence, the dying tumor exposes the immune system to the unique molecular fingerprints of the cancer. Researchers began to wonder whether cryoablation might function as a kind of in situ cancer vaccine.

This possibility became even more exciting with the rise of immunotherapy. Modern immunotherapy has transformed cancer treatment by helping the immune system recognize and attack tumors. Some patients with advanced cancers have experienced astonishing recoveries. Yet these therapies often come with severe side effects because they activate the immune system throughout the body. They are also extraordinarily expensive and given intravenously in a relatively large dose that travels throughout the body, with the potential for severe side effects.

Researchers asked a crucial question. What if immune stimulating drugs could be injected directly into the peripheral margins of cancerous tumors?  This approach became the focus of another major study involving Littrup and his collaborators. Instead of delivering immunotherapy intravenously, physicians combined small volume cryoablation of a portion of a target tumor with peritumoral injections of checkpoint inhibitors and other immune stimulating agents.

The concept was powerful in its simplicity. First, cryoablation damages the tumor and releases cancer antigens. Then localized immunotherapy activates immune cells directly within the tumor environment. The goal is not merely to destroy the treated tumor but to teach the immune system to hunt down cancer cells throughout the body. 

The researchers called this strategy Multiplex IntraTumoral Immunotherapy, or MITI. In a first in human clinical trial involving patients with advanced metastatic cancers who had already failed standard treatments, the results were remarkable. Some patients experienced stabilization of disease. Others saw tumors shrink not only at treated sites but also in distant metastases that had never been directly targeted.

This phenomenon is known as the abscopal effect, one of the most intriguing and mysterious responses in cancer medicine. Somehow, a local treatment triggers a systemic immune attack against tumors elsewhere in the body.

Two patients achieved especially dramatic outcomes, including complete responses that hinted at the possibility of durable cancer control. While the trial was small and further research is urgently needed, the results suggest that combining cryoablation with localized immunotherapy could become a highly cost-effective strategy for turning tumors into personalized cancer vaccines.

The implications are profound. Traditional cancer vaccines have struggled because cancers differ enormously between patients. But a patient’s own tumor already contains the exact antigens needed to train their immune system.

In this sense, the tumor itself becomes the vaccine factory. What makes this vision especially compelling is its practicality. Unlike many cutting-edge cancer technologies that require billion dollar facilities or rare equipment, imaging systems and cryoablation technologies already exist in hospitals throughout much of the world. The infrastructure needed for widespread implementation may be far more achievable than many realize.

This matters because cancer is not only a medical crisis but also an economic one. Many modern therapies cost hundreds of thousands of dollars per patient. Even wealthy healthcare systems struggle under the burden. In lower income countries, access to advanced treatment remains limited for millions of people.

A more affordable, minimally invasive, image guided approach could fundamentally reshape global cancer care. The convergence of these technologies also reflects a broader shift in medicine. Increasingly, researchers are moving away from viewing diagnosis and treatment as separate processes. Instead, the future may belong to theranostics, systems that combine therapy and diagnostics into a single integrated platform.

In such a future, an ultrasound tomography device might first detect a suspicious lesion, characterize its physical properties, guide a small sound-based ablation procedure, monitor temperature changes in real time, deliver drug carrying microbubbles into the tissue, and stimulate an immune response, all within the same technological ecosystem.

That vision still requires significant clinical validation. Many scientific, engineering, and regulatory hurdles remain. Larger trials are needed to determine which patients benefit most, how treatments should be optimized, and how durable these responses can become.

Yet the conceptual foundation is already in place. The work led by Prof. Peter Littrup and his collaborators demonstrates that medicine’s next revolution may not come from a single miracle drug or device. Instead, it may emerge from the thoughtful synthesis of multiple technologies that already exist but have rarely been combined in such innovative ways.

At its heart, this research carries a hopeful message. Cancer treatment does not necessarily have to become more aggressive, more toxic, or more expensive to become more effective. Sometimes the greatest breakthroughs arise from working with the body rather than against it. Freezing a tumor, guiding sound through tissue, and teaching the immune system to recognize danger may ultimately prove more powerful than many of the harsher approaches that dominate cancer care today.

And for the 1 million people in the U.S., and the 11 million people around the world with Parkinson’s disease, hope has been expanded from currently implanted deep brain stimulating devices to much less invasive, theranostic ultrasound tomography of the brain. Considering that the prevalence of patients living with metastatic cancer in the U.S. is just under 700,000 people, it would not be that surprising if a “good” tool for cancer could even more rapidly become a “great” tool for Parkinson’s and other neurologic brain diseases.

It is no wonder that Prof. Littrup is frequently heard saying, “Bless, help and heal me, that I may better bless, help and heal others”.  Sweet dreams, indeed!